Pancreatic Cancer Stem Cells: Their Role in Pancreatic Cancer Patient Outcomes and What Is Future?

  • Muzzamal Habib Steward St. Elizabeth Medical Center, Tufts University School of Medicine. Boston, MA, USA
  • Muhammad Wasif Saif Tufts Medical Center, Tufts University School of Medicine. Boston, MA, USA
Keywords: Pancreatic Neoplasms, Stem Cells, Survival


There is emerging evidence that stem cells might be playing an important role when it comes to cancer aggressiveness, metastasis, recurrence, resistance to chemotherapy and overall survival in hematologic malignancies as well as solid tumors including pancreatic adenocarcinoma. We review Abstract #e15058 presented at the 2013 ASCO Annual Meeting in Chicago by Andrikou et al.. Pancreatic cancer patients over-expressing pancreatic cancer stem cell markers were associated with aggressive tumors and worse survival.

Image: Model of hierarchical organization of pancreatic cancer cell population.


Download data is not yet available.


Li, C., et al., Identification of pancreatic cancer stem cells. Cancer Res, 2007. 67(3): p. 1030-7.

Rasheed, Z.A., et al., Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst, 2010. 102(5): p. 340-51.

Hermann, P.C., et al., Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007. 1(3): p. 313-23.

Li, C., et al., c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology, 2011. 141(6): p. 2218-2227 e5.

Kim, M.P., et al., ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One, 2011. 6(6): p. e20636.

Adikrisna, R., et al., Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology, 2012. 143(1): p. 234-45 e7.

Andrikou K, Faloppi L, Loretelli C, Mandolesi A, Bearzi I, Cascinu S. Expression of stem cell markers in pancreatic ductal adenocarcinoma and clinical relevance. J Clin Oncol 2013; 31(Suppl.): Abstract #e15058.

Jemal, A., et al., Cancer statistics, 2007. CA Cancer J Clin, 2007. 57(1): p. 43-66.

Bonnet, D. and J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997. 3(7): p. 730-7.

Graham, S.M., et al., Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 2002. 99(1): p. 319-25.

Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 2003. 100(7): p. 3983-8.

Miki, J., et al., Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res, 2007. 67(7): p. 3153-61.

O’Brien, C.A., et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 2007. 445(7123): p. 106-10.

Frank, N.Y., et al., ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res, 2005. 65(10): p. 4320-33.

Singh, S.K., et al., Identification of a cancer stem cell in human brain tumors. Cancer Res, 2003. 63(18): p. 5821-8.

Jiao, J., et al., Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One, 2012. 7(8): p. e42564.

Muraro, M.G., et al., CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med, 2012. 1(8): p. 592-603.

Tachezy, M., et al., ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One, 2012. 7(6): p. e39018.

Tachezy, M., et al., ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer, 2012. 131(2): p. 396-405.

Honecker, F., et al., New insights into the pathology and molecular biology of human germ cell tumors. World J Urol, 2004. 22(1): p. 15-24.

Jones, T.D., et al., OCT4: A sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res, 2004. 10(24): p. 8544-7.

de Jong, J., et al., Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J Pathol, 2005. 206(2): p. 242-9.

Iczkowski, K.A., et al., Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors. Hum Pathol, 2008. 39(2): p. 275-81.

Palma, I., et al., Utility of OCT3/4, TSPY and beta-catenin as biological markers for gonadoblastoma formation and malignant germ cell tumor development in dysgenetic gonads. Dis Markers, 2013. 34(6): p. 419-24.

Ling, G.Q., et al., Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. Oncol Lett, 2012. 4(6): p. 1264-1268.

Tan L, Sui X, Deng H, Ding M. Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 2011; 6(8):e23383.

Model of hierarchical organization of pancreatic cancer cell population
How to Cite
HabibM., & SaifM. (2013). Pancreatic Cancer Stem Cells: Their Role in Pancreatic Cancer Patient Outcomes and What Is Future?. JOP. Journal of the Pancreas, 14(4), 401-404.
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013